https://biotechmorning.com/news/fda-approves-cancer-killing-virus-melanoma Biotech Morning en 2026-08-18T14:17:37.589Z The FDA Just Approved a Cancer-Killing Virus. Yes, Really. https://biotechmorning.com/news/pathos-ai-alphamab-jskn016-2-billion-deal Biotech Morning en 2026-08-18T14:16:53.383Z The $2 Billion Bet on a Cancer Drug You've Never Heard Of https://biotechmorning.com/news/regeneron-eye-trial-halted-safety-review Biotech Morning en 2026-08-18T14:15:56.760Z Regeneron's Eye Just Blinked https://biotechmorning.com/news/leo-pharma-dersimelagon-deal-435-million Biotech Morning en 2026-08-18T14:15:16.400Z LEO Pharma Just Paid $435M for a Drug That Isn't Approved Yet https://biotechmorning.com/news/amylyx-avexitide-post-bariatric-hypoglycemia-comeback Biotech Morning en 2026-08-18T14:14:32.092Z Amylyx's Unlikely Comeback Started With a Sugar Crash https://biotechmorning.com/news/argenx-vyvgart-myositis-phase-3-win Biotech Morning en 2026-08-18T14:13:42.031Z Argenx Just Cracked Open a New Market (With One Asterisk) https://biotechmorning.com/news/fulcrum-slate-medicines-reverse-merger-nasdaq Biotech Morning en 2026-08-18T14:12:56.717Z Fulcrum Gutted Its Pipeline. Then It Became Someone Else's Ride to Nasdaq. https://biotechmorning.com/news/evaxion-kills-tumor-vaccine-bets-on-brain-cancer Biotech Morning en 2026-08-18T14:12:14.076Z Evaxion Just Killed Its Tumor Vaccine. What It's Betting On Instead Is Wild. https://biotechmorning.com/news/sanofi-blueprint-medicines-layoffs-post-acquisition Biotech Morning en 2026-08-18T14:11:25.480Z Sanofi Bought Blueprint Medicines for $9.5 Billion. Then Cut a Third of Its People. https://biotechmorning.com/news/moonlake-sonelokimab-izar-1-trial-results-wall-street Biotech Morning en 2026-08-17T14:17:08.457Z MoonLake's Drug Aced Its Biggest Test. Wall Street Shrugged. https://biotechmorning.com/news/oncosil-fda-approval-bile-duct-cancer-device Biotech Morning en 2026-08-17T14:16:20.663Z A Tiny Radioactive Implant Just Crashed the Bile Duct Cancer Party https://biotechmorning.com/news/eyepoint-duravyu-lugano-phase-3-wet-amd-mixed-results Biotech Morning en 2026-08-17T14:15:38.434Z EyePoint's Eye Drug Worked — Except When It Didn't https://biotechmorning.com/news/biotech-vc-funding-gap-widens-h1-2026 Biotech Morning en 2026-08-17T14:14:46.884Z $9.1 Billion Poured Into Biotech. Most Startups Didn't See a Dime. https://biotechmorning.com/news/sandoz-henlius-biosimilar-deal-china Biotech Morning en 2026-08-17T14:14:03.033Z Sandoz Is Buying Its Biosimilar Future From China https://biotechmorning.com/news/lilly-370m-ion-channel-omniab-deal Biotech Morning en 2026-08-17T14:13:14.925Z Lilly's $370M Bet on the Drug Targets Nobody Wanted https://biotechmorning.com/news/astrazeneca-bispecific-antibody-trial-flop Biotech Morning en 2026-08-17T14:12:26.062Z AstraZeneca's Big Bet on a Two-for-One Cancer Drug Just Flopped https://biotechmorning.com/news/ribox-circular-rna-in-vivo-car-therapy-fda-clearance Biotech Morning en 2026-08-17T14:11:37.768Z The First Drug That Builds Cancer-Killing Cells Inside Your Body